The effectiveness of a Vitamin K2 analog on the recurrence of HCC after curative therapy

The effectiveness of a Vitamin K2 analog on the recurrence of HCC after curative therapy - Vitamin K2 therapy and HCC recurrence after curative therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000431

Enrollment

Registered

2014-01-20

Start date

2006-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with HCC after curative treatment

Interventions

oral administration of Vitamin K2 analog without administration of Vitamin K2 analog

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a)above 20 years and under 80 years b)Patients underwent curative treatment of HCC

Exclusion criteria

Exclusion criteria: (a)A planned case of postoperative interferon therapy after curative treatment of HCC (b) other malignancies (c)Vitamin K allergy (d)receiving warfarin or aspirin (e)ruptured HCC (d)Operation-related death (e)HCC reccurence detected via CT within 3 or 4 weeks (f)judged to be inadequate case of this clinical test for other reasons by doctors

Design outcomes

Primary

Measure	Time frame
cumulative tumor recurrence rate	—

Secondary

Measure	Time frame
survival	—

Countries

Japan

Contacts

Public ContactYoshitaka Takuma

National Hospital Organization Iwakuni Clinical Center Internal Medicine

takuma@enjoy.ne.jp0827-32-7121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026